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Background: Drug shortages are a global problem. While extensively studied in the United States, numbers about
drug shortages in European countries are scarce. This study aims to collect and present data about drug shortages
in European countries.
Methods: A reporting template for the collection of data about drug shortages was designed based on a literature
search. Countries offering a reporting system for drug shortages such as Belgium, the Netherlands, England, Italy,
France, Germany and Spain were included in this study. Data about the characteristics of the drugs in shortage and
the causes of the shortage were collected from publicly available online reporting systems. Descriptive analyses
were performed.
Results: Drug shortages included in the considered reporting systems can be characterized as branded, oral drugs
that affect different disease domains. When considering essential medicines and oncology drugs, generic
injectables are more involved. Causes for drug shortages are largely underreported. In case the cause is known,
production problems take the lead.
Conclusions: Reporting of drug shortages in Europe needs to be standardized and more transparency about the
reasons for drug shortage is required to investigate the problem. A link between production problems and market
attractiveness and market capacity is recognized to be at the root of drug shortages in U.S. Such insights are highly
lacking in Europe. Monitoring of the effect of national and European health policies on the sustainability of the
drug market is required to present fundamental solutions and to tackle the problem of drug shortages in Europe.
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Drug shortages are recognized as a global problem by the
World Health Organization (WHO) [1]. Drug shortages
can be defined as a shortcoming in the supply of a medi-
cinal product which makes it impossible for suppliers to
meet the demand for the product at patient level. It affects
all stakeholders of the health care system such as patients,
pharmacists, clinicians, the pharmaceutical industry and
policy makers. Patients need to switch to an alternative
therapy which may cause adverse effects, increased inci-
dence of medication errors and disease progression [2,3].
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unless otherwise stated.costs due to switchovers to alternative therapies and in-
creased workload to manage the shortage [2,3]. The origin
of a drug shortage problem can possibly be located at the
supply and/or demand side. At the level of drug supply,
manufacturing difficulties, unavailability of raw materials
and natural disasters are reported [4,5]. Cessation of the
production of a drug can also be an economic decision of
the manufacturer [5]. Additionally, the supply side can be
influenced by policy measures such as restricted drug pro-
duction or allocation and quality requirements [6]. At the
demand side, causes of drug shortage proposed in litera-
ture are unexpected increase in demand, unforeseen shifts
in clinical practice and parallel trade [6].
Drug shortages affect the health care system in the
United States (U.S.) more than ever before. Numbers ofl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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2005 to more than 200 reported drug shortages in 2010
[3,4,6]. Since 2011, the U.S. Food and Drug Administra-
tion (FDA) has taken initiatives to prevent and mitigate
the impact of drug shortages in the U.S. Although
pharmaceutical manufacturers cannot be forced to pro-
duce (an additional amount of) a particular drug, FDA
aims to provide knowledge about drug shortages to
health care providers in advance of the shortage [5].
Therefore, manufacturers are mandated to notify the
FDA about potential discontinuations in supply of drugs
for serious or life-threatening conditions [6]. A more ex-
tensive database of U.S. drug shortages is maintained by
the American Society of Health-system Pharmacists
(ASHP). Monitoring of drug shortages does not only
promote early anticipation of drug shortages by health
care workers, it does also provide a source for extensive
data analysis. It has been reported that U.S. drug short-
ages are mostly affecting the generic injectable market
with majority of drugs in shortage indicated for oncology
indications [5-7].
Although exact figures about drug shortages in Europe
are lacking, the emerging number of reports and studies
about drug shortages in European countries leave no
doubt that the problem is also affecting the European
drug market [8-14]. While the consequences of drug
shortages are likely to be comparable between U.S. and
Europe, the causes are expected to depend on specific
features of the health care market, determined by the
regulatory framework and health policy applied in a
particular country. There is no centralized database col-
lecting information about drug shortages in European
countries. Given that understanding of the “what” and
“why” is essential to present fundamental solutions, the
goal of this study is to collect and present data about
drug shortages in European countries. By way of a case
study, special focus will go to oncology drugs as short-
ages in the U.S. are mostly occurring in this disease do-
main, while the impact in Europe is unknown. Shortages
of oncology drugs pose a special challenge due to the
number of patients involved, the multiple indications
that one oncology drug often has and the narrow thera-
peutic window of oncology therapies in which small
adjustments in dose can have a tremendous effect.
Methods
A reporting template was designed to collect the data
about drug shortages in Europe in a standardized, sys-
tematic and reproducible way. The features included in
this reporting template aim to cover all aspects involved
in typology and causes of drug shortages, based on a lit-
erature search. The literature was searched through
Pubmed and Embase between May and June 2013 by a
combination of following search terms: drug purchasing,drug marketing, drug supply, drug shortage, drug crisis,
drug in short supply, stock problem. Articles concerning
drug shortages, published in English between 2010
and 2013, were selected to ensure up-to-date information.
Further, websites of the following international and
European health care associations were consulted: World
Health Organization (WHO), European Medicines Agency
(EMA), European Generics Association (EGA), European
Association of Hospital Pharmacists (EAHP), European
Association of Pharmaceutical Full-line Wholesalers (GIRP),
International Society for Pharmaco economics and Out-
comes Research (ISPOR), Food and Drug Administration,
American Society of Health System Pharmacists (ASHP),
and European Federation of Pharmaceutical Industries
and Associations (EFPIA). Next, websites of national
health authorities of European countries were checked for
the presence of a reporting system concerning drug short-
ages. Based on this first survey, Belgium, the Netherlands,
England, Italy, Germany, Spain and France were selected
for inclusion in this study based on the presence of a
reporting system for drug shortages (Table 1). The report-
ing systems presented in Table 1 were consulted in May
3013 and the designed reporting template was used to
collect data about drug shortages.
Before the start of the analyses the data were checked
for duplicates and the data set was filtered to include
prescription drugs only. Additionally, oncology drugs
were selected based on the Anatomic Therapeutic
Chemical Classification System (ATC) code L01 and L03
for a sub-analysis. Given that literature about typology
of drug shortages is mainly limited to U.S. studies, a
sub-analysis was also performed for drugs defined as es-
sential medicines by the WHO to increase comparability
with U.S. and thus the literature [15]. Descriptive statis-
tics on the characteristics and causes of drugs shortages
were calculated.
Results
The reporting template was designed to collect the follow-
ing information (Figure 1): country of shortage, name of
the drug, active substance, dose(s) of the drug affected
by shortage, route of administration, listed as essential
medicine by the WHO or not, marketing authorization
obtained via centralized procedure or not, branded or gen-
eric drug, ATC code according to the WHO Collaborating
Centre for Drug Statistics Methodology [16], requirement
of prescription, drug used in hospital setting only or com-
munity pharmacy, start date of the shortage, end date
of the shortage, concerned company, cause, existence of
alternative (generic) drugs, source of information. The
route of administration was classified in four groups: oral,
injectable, insert or implant, topical or dermatological.
The causes were fully described in the reporting template
during the collection of data for this study.
Table 1 Data sources consulted to complete the reporting template and scope of the reporting systems
Country National shortage reporting system Reporter Drugs included in reporting system National drug formulary for hospitals
or community pharmacy consulted to
complete reporting template
Belgium Federal Agency for Medicines and
Health Products (FAGG)
Marketing authorization holders Drug for which unavailability cause a
risk for public health and have no
therapeutic alternative
Belgian Centre for Pharmacotherapeutic
Information (BCFI)
Farmaco-contingentering.be Pharmacists Products subjected to supply quota
The Netherlands Farmanco.nl Marketing authorization holders,
wholesalers, pharmacists
Unlimited Geneesmiddelenrepertorium.nl
England Pharmaceutical Services Negotiation
Committee (PSNC)
Pharmacists Products for community pharmacy only Eudrapharm
Italy Italian Medicines Agency (AIFA) Marketing authorization holders,
health care providers, health
departments, patients or associations
Unlimited Italian Drug Formulary (AIFA)
Eudrapharm
Germany Federal Institute for Drugs and
Medical Devices (Bfarm)
Marketing authorization holders Products for treatment of threatening
or serious diseases for which no
alternatives are available
Federal Institute for Drugs and Medical
Devices (Bfarm)
Eudrapharm
Spain Spanish Agency for Medicines and
Health Products (aemps)
Marketing authorization holders
or health authorities of autonomous
communities
Unlimited Spanish Agency for Medicines and
Health Products (aemps)
France National Agency for Safety of Drugs
and Health Products (ansm)
Pharmacists and hospitals Drug for which unavailability cause a risk
for public health and have no therapeutic
alternative
National Agency for Safety of Drugs





















Figure 1 Reporting template for drug shortages.
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data for this study. The different reporting systems con-
sulted in this study each rely on particular reporters to
obtain the information and the scope of drugs presented
in the reporting system differs between different report-
ing systems. The reporter and scope of the reporting
system is presented in Table 1.
Information about 671 drug shortages was collected.
Figure 2 shows the proportion of shortages reported in
each country considered in this study. In France, the
reporting system notified one shortage that happened in
2005 and one shortage recorded in 2009. In the
Netherlands, the reporting system mentioned a shortage
that occurred in 2007. Start dates of all other shortages
included in the reporting systems are between January
2010 and August 2013. In five percent of the cases (31/
671), information about the start data was however not
reported. In 68% (459/671) information about the pre-
dicted end date of shortage was not available. Seventythree percent of the shortages for which information
about the predicted end of the shortage (154/212) was
available, was presented as a permanent cessation.
For those cases for which both the start date as well as
the end date were available, the median duration of the
shortage was 139 days (n = 54). Based on available infor-
mation about start date and end date of the shortages,
on June 1st 2013, 21 shortages were still ongoing. In 6%
of the cases for which the start date was available (38/
640) a start date after June 1st 2013 was mentioned and
the shortages was thus announced in advance.
Nine percent (61/671) concern drugs that obtained
marketing authorization through the centralized proced-
ure of EMA, involving 32 different products. EMA re-
ported the shortage for only seven of these products.
Over 50% of reported shortages affected medicines
included in one of the five major ATC classes: cardiovas-
cular system, anti-infectives for systemic use, antineo-
plastic and immune modulating agents and the nervous
Figure 2 Proportion of reported shortages per country. n = 161.
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ages (200/671) affected drugs defined as essential medi-
cines by the WHO. Further results additionally focus on
oncology drugs and drugs defined as essential medicines
by the WHO.
Overall, 63% of reported drug shortages were branded
drugs (424/671) and only 37% were generics. For 42% of
these branded drugs (178/424), generics already entered
the market while in the other 58% of the cases, no com-
petitors were marketed yet. At the same time, 76% of
permanent shortages (117/154) affected branded drugs.
For essential drugs, 55% of reported drugs in shortage
(110/200) were branded drugs. For oncology drugs 46%
of the shortages affected branded drugs (33/71).
The cause of the drug shortage was only specified in
36% of the cases (236/671). In order to increase homogen-
eity in the data obtained from different reporting systems,
reported causes were classified in five broad groups i.e.Figure 3 Proportion of reported drugs per Anatomic Therapeutic Che
products, insecticides and repellents, products for the respiratory system, p
forming organs and dermatologicals. These are all grouped for the sake ofproduction problems, economic reasons, other causes,
multiple reasons and unknown cause (Table 2). When the
cause for the shortage was reported, production problems
and causes defined under the group “other” were leading
for overall shortages as well as for shortages of essential
medicines (Figure 4a and 4b). For oncology drugs, short-
ages were mostly due to production problems and com-
mercial reasons however the number of observations was
very limited (Figure 4c). The class of production problems
presents technical problems, quality related issues and
shortage of active pharmaceutical ingredients (Table 2).
However not all reporting systems distinguished between
these different production problems (Table 2). The group
defined under “other causes” included a variety of causes
that were only reported a single time or were only re-
ported in case of one country (Table 2). The majority of
causes defined under “other” presented regulatory prob-
lems reported by Italy. Although EMA reported only amical Class. Drugs classified in the group “other” include antiparasitic
roducts for the sensory organs, drugs affecting blood and blood
clarity. n = 161.
Table 2 Causes for drug shortages reported in national
reporting systems
Production problems
Italy Production problem (at European level)
France Problems with production
Impurities found in syringe
Lack of active substance
Contamination particular lots
Germany Production problem
Technical defect in the production procces
Problems with manufacturing the solvent
Inability to meet the demand due to
problem GMP compliance
Belgium Production problem
Re-engineering of the process and equipment
at sterile production site
Availability of raw material
The Netherlands Production problems
Delay startup new production line
Problems with raw materials




Spain Problems with sterility based on inspection
in France and UK
Economic reason
Italy Commercial problem
Belgium Stop due to commercial reasons





France Mistake in labeling
England Shortage of active pharmaceutical ingredient
Stop supply of alternative
Spain Marketing authorization cancelled
Belgium Limited stock because unavailability of
alternative product
Problem of stock





Delay in delivery of new packages
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national reporting systems, the causes behind the shortage
were however more unfolded compared to the national
reporting systems. Production problems were described as
manufacturing defects that prevent the patients to inject
the full dose, shutdown of production site, manufacturing
problems leading to quality issues, shutdown of filling line
and quality batched leading to a recall of several batches
and stopping of production. Other causes mentioned by
EMA are delay caused by accidental spillage and capacity
problems at the laboratory were the drug is manufactured.
The majority of reported drugs in short supply were
oral drugs, followed by injectables (Figure 5a). For essen-
tial drugs and oncology drugs in short supply, the major-
ity of reported drugs were injectables, followed by oral
drugs (Figure 5b-c).
Discussion
This study investigated drug shortage reporting systems
from seven European countries, in order to collect and
present data about drugs in short supply in Europe. The
results characterized drug shortages in European coun-
tries as oral, branded drugs that affect a broad range of
disease domains. Causes for drug shortages were widely
underreported in European countries; however produc-
tion problems in a broad sense were suggested to be the
major cause.
These results are based on eight different reporting
systems presenting shortages in seven countries. Drug
shortages are a dynamic problem and databases need
regular updates, so data included in this study can
present only a snapshot of the problem. Further, each
system applies its own standards for reporting shortages
so reporting bias needs to be considered with regard to
the results of this study. First, reporting systems each
have a different scope. The scope of the Italian reporting
system is the broadest compared to other systems con-
sidered in this study, since there are no limitations with
regard to the type of drugs included in the reporting
system, and all stakeholders of the health care system
are eligible for reporting. Only a limited proportion of
the reported shortages were mentioned in advance, com-
plicating early anticipation by health care workers and
jeopardizing patient care. For the cause of drug short-
ages, it is unclear whether particular causes do not occur
in a country or if the reporting system is not sufficiently
specified to identify these causes. Causes of drug short-
age are categorized in broad groups and could only be
analyzed summarily in this study. Considering drug
shortages for which information about the cause is avail-
able, production problems take the lead. It is generally
assumed that injectables are most susceptible to produc-
tion problems and quality defects compared to other for-
mulations, due to the complexity of the manufacturing
a b c
Figure 4 Proportion of the reported drugs per cause for drug shortages. The proportion of drugs per cause is shown for a) overall drugs
(n = 171), b) essential drugs (n = 200) and c) oncology drugs (n = 71).
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economic issues, such as price competition for generic
injectables, which reduces profitability and market at-
tractiveness and discourages investments in quality of
generics by the manufacturer [1,6,7,17]. While the the-
ory of economic root causes behind drug shortages was
first only hypothesized in scientific literature [5,6,17],
it is recently recognized in the revised action plan
against drug shortages by the FDA in the U.S., published
in October 2013 [18,19]. In Europe however, no efforts
are yet made to unveil the root causes for drug shortages
[18,20]. Economic root causes behind drug shortages are
supposedly also not reported because it can lead to a nega-
tive perception about the marketing authorization holder.
Moreover, drug shortages in considered European coun-
tries were not affecting generic drugs in the majority of
reported causes although this observation may be biased
since some of the considered reporting systems limit theira b
Figure 5 Proportion of the reported drugs per route of administratio
a) overall drug (n = 671), b) essential drugs (n = 200) and c) oncology drudata to drugs without alternative treatments. When how-
ever focusing on essential medicines and oncology drugs,
the importance of generic injectables in shortages in-
creased. The larger share of branded drugs in European
drug shortages may be explained by international refer-
ence pricing applied in a number of European countries,
proposed to have a downwards effect on prices for
branded products [20]. However, particular regulatory
frameworks present at national and European level are
potential candidates for the root cause of production
problems. Capacity problems can be caused by tendering
procedures, which intend to grant the most favorable
reimbursement for those products that are offered at the
lowest price during a public procurement and are widely
applied in European countries. In some cases supply is
even reserved for products that won the tender, and the
marketing of the drug becomes less profitable and less
attractive for manufacturers who did not win. When thec
n. The proportion of drugs per route of administration is shown for
gs (n = 71).
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ably low, tendering will reduce the capacity of the market
to step up supply if needed and pave the way to drug
shortages [21]. Further, some manufacturers manage and
restrict supply to wholesalers by introduction of supply
quotas with the aim to ensure patient access and obtain
their market share. Supply quotas are currently more
under the suspicion of causing drug shortages instead of
avoiding them because manufacturers may not be able to
cope with an (unexpected) increase in demand [20]. In
order to ensure sustainable drug supply, the allocation of
quotas must be based on reliable data and able to cope
with fluctuations in demand instead of being based on his-
toric data, as mostly is the case [20]. Also interaction be-
tween different European member states can occur and
affect the drug supply chain. The European Union is a sin-
gle market with free movement of goods. Intellectual
property rights are exhausted once a product has been put
on the market with permission of the patent holder. This
allows wholesalers to buy products in countries with low
prices and sell them at high margins in countries with high
price for the particular drug. This phenomenon of parallel
trade can effectuate drug shortage when export of the
product is not foreseen and cannot be anticipated [22].
Additionally, when imported products are sold cheaper
than prices valid in that country, marketing of the product
by national suppliers can also be discouraged [22]. The
impact of parallel trade on drug shortages is poorly stud-
ied but heterogeneous price setting between European
countries makes its role in drug shortages plausible.
Further understanding of the drug shortage problem
in Europe however requires improved reporting systems
that allow insights in the reason for shortages. National
health authorities need to follow-up the consequence of
national policies on the sustainability of the market and
the effect of interactions between countries on national
drug shortages needs to be monitored at European level.
The European Medicines Agency (EMA) already re-
ported about drug shortages in the past although publi-
cally available information was restricted, incomplete
and limited to a small number of drugs, illustrating the
need for a profound European initiative.
Conclusions
Drug shortages are a global and increasing problem.
Production problems seem the leading cause of short-
ages in European countries and U.S. but the characteris-
tics of drugs in shortage can differ between these two
regions. A strong link between production problems and
market attractiveness is proposed and this needs to be
investigated in Europe. Therefore, more profound in-
sights in the underlying causes are required. Cost-
containment measures need to be applied with scrutiny
to ensure that all players of the drug supply chain canundertake their activities in a sustainable way. Therefore,
national health authorities need to monitor the impact
of national policies concerning price and reimbursement
on availability of drugs. Additionally, further initiatives
at European levels are required to monitor the inter-
action between national European markets. In that way,
the lack of market capacity and reduced market attract-
iveness from the perspective of every player in the drug
supply chain can be timely traced and anticipated and a
fundamental solution for drug shortages can be devel-
oped, and this with the aim of guaranteeing the availabil-
ity of medicinal products to the patient.
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